Pharmacogenomics in the clinic

MV Relling, WE Evans - Nature, 2015 - nature.com
After decades of discovery, inherited variations have been identified in approximately 20
genes that affect about 80 medications and are actionable in the clinic. And some …

The OncoArray Consortium: a network for understanding the genetic architecture of common cancers

CI Amos, J Dennis, Z Wang, J Byun… - Cancer epidemiology …, 2017 - aacrjournals.org
Background: Common cancers develop through a multistep process often including
inherited susceptibility. Collaboration among multiple institutions, and funding from multiple …

[HTML][HTML] Response and toxicity to cytarabine therapy in leukemia and lymphoma: from dose puzzle to pharmacogenomic biomarkers

R Di Francia, S Crisci, A De Monaco, C Cafiero, A Re… - Cancers, 2021 - mdpi.com
Simple Summary In this review, the authors propose a crosswise examination of cytarabine-
related issues ranging from the spectrum of clinical activity and severe toxicities, through …

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer

F Aminkeng, AP Bhavsar, H Visscher, SR Rassekh… - Nature …, 2015 - nature.com
Anthracyclines are used in over 50% of childhood cancer treatment protocols, but their
clinical usefulness is limited by anthracycline-induced cardiotoxicity (ACT) manifesting as …

Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors

LB Travis, WD Wahnefried, JM Allan… - Nature reviews Clinical …, 2013 - nature.com
Second and higher-order malignancies now comprise about 18% of all incident cancers in
the USA, superseding first primary cancers of the breast, lung, and prostate. The occurrence …

[HTML][HTML] Cancer: An unknown territory; rethinking before going ahead

A Upadhyay - Genes & diseases, 2021 - Elsevier
Cancer is a disease of altered signaling and metabolism, causing uncontrolled division and
survival of transformed cells. A host of molecules, factors, and conditions have been …

Predicting cancer drug response using a recommender system

C Suphavilai, D Bertrand, N Nagarajan - Bioinformatics, 2018 - academic.oup.com
Motivation As we move toward an era of precision medicine, the ability to predict patient-
specific drug responses in cancer based on molecular information such as gene expression …

Polygenic risk scores in clinical psychology: bridging genomic risk to individual differences

R Bogdan, DAA Baranger… - Annual review of clinical …, 2018 - annualreviews.org
Genomewide association studies (GWASs) across psychiatric phenotypes have shown that
common genetic variants generally confer risk with small effect sizes (odds ratio< 1.1) that …

Determining the optimal dose in the development of anticancer agents

RHJ Mathijssen, A Sparreboom, J Verweij - Nature reviews Clinical …, 2014 - nature.com
Identification of the optimal dose remains a key challenge in drug development. For cytotoxic
drugs, the standard approach is based on identifying the maximum tolerated dose (MTD) in …

Personalized pharmacogenomics: predicting efficacy and adverse drug reactions

M Pirmohamed - Annual review of genomics and human …, 2014 - annualreviews.org
Drug response varies between individuals owing to disease heterogeneity, environmental
factors, and genetic factors. Genetic factors can affect both the pharmacokinetics and …